Cantor Fitzgerald Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $25
ADMA Biologics: Strong Growth Prospects and Stability Drive Buy Rating
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Announces Target Price $32
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating
Buy Rating Affirmed for ADMA Biologics Amid Transition to New Auditor and Growth Prospects
Cantor Fitzgerald Maintains ADMA Biologics(ADMA.US) With Buy Rating, Raises Target Price to $25
ADMA Biologics Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on ADMA Biologics, Maintains $25 Price Target
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Announces Target Price $28
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $24
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Announces Target Price $24
ADMA Biologics Is Maintained at Strong Buy by Raymond James
ADMA Biologics Analyst Ratings
H.C. Wainwright Maintains ADMA Biologics(ADMA.US) With Buy Rating, Raises Target Price to $26
Key Takeaways From ADMA Biologics Analyst Ratings
H.C. Wainwright Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $18
Maintaining Buy Rating on ADMA Biologics Amid Auditor Resignation: Confidence in Fiscal Health and Compliance
ADMA Biologics (ADMA) Receives a Buy From Mizuho Securities